Improving outcomes with anti-BCMA bispecific antibodies with attention to infection - Top-Institutions - MDSpire

Improving outcomes with anti-BCMA bispecific antibodies with attention to infection

  • By

  • Andrew J. Yee

  • July 8, 2024

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy
    • Multiple Myeloma

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy
    • Multiple Myeloma

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma
    • Immunotherapy

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy
    • Multiple Myeloma

  • #5

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy
    • Multiple Myeloma

Original Source(s)

Improving outcomes with anti-BCMA bispecific antibodies with attention to infection

  • by Andrew J. Yee

  • July 8, 2024

Related Content

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

SARS-CoV-2 infection complicated by acute longitudinally extensive transverse myelitis and pulmonary embolism: a case report